Research
Hormonal
Amylin receptor activators may have an adverse effect profile more favorable than that of GLP-1 receptor activators.
Amylin receptor activators may be a safer alternative to GLP-1 receptor activators for patients.
StrongSupportsmedium confidence
Amylin receptor activators may have an adverse effect profile more favorable than that of GLP-1 receptor activators.
Why this rating
Based on the review of available information regarding drug profiles.
Source
A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy
Sang Min Lee · Current Drug Targets · 2025
DOI 10.2174/0113894501398624250819070004
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →